According to the Complaint, Anavex Life Sciences Corporation investigates, manufactures, and markets pharmaceuticals for central nervous system (CNS) disorders. Anavex’s primary product is blarcamesine (Anavex 2-73). Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders. One such disorder Anavex has investigated is Rett syndrome, a neurodevelopmental disorder affecting primarily females. The Complaint alleges that Defendants violated Section 10(b) of the 1934 Act by failing to disclose pertinent information relevant to the Company or, alternatively, providing information about the Company which was misleading or deceptive.